Elevated level of lysophosphatidic acid among patients with HNF1B mutations and its role in RCAD syndrome: a multiomic study.
Metabolomics
; 18(3): 15, 2022 02 18.
Article
em En
| MEDLINE
| ID: mdl-35179657
ABSTRACT
INTRODUCTION:
Patients with hepatocyte nuclear factor-1 beta (HNF1B) mutations present a variable phenotype with two main symptoms maturity onset diabetes of the young (MODY) and polycystic kidney disease (PKD).OBJECTIVES:
Identification of serum metabolites specific for HNF1Bmut and evaluation of their role in disease pathogenesis.METHODS:
We recruited patients with HNF1Bmut (N = 10), HNF1Amut (N = 10), PKD non-dialyzed and dialyzed (N = 8 and N = 13); and healthy controls (N = 12). Serum fingerprinting was performed by LC-QTOF-MS. Selected metabolite was validated by ELISA (enzyme-linked immunosorbent assay) measurements and then biologically connected with HNF1B by in silico analysis. HepG2 were stimulated with lysophosphatidic acid (LPA) and HNF1B gene was knocked down (kd) by small interfering RNA. Transcriptomic analysis with microarrays and western blot measurements were performed.RESULTS:
Serum levels of six metabolites including arachidonic acid, hydroxyeicosatetraenoic acid, linoleamide and three LPA (181, 182 and 204), had AUC (the area under the curve) > 0.9 (HNF1Bmut vs comparative groups). The increased level of LPA was confirmed by ELISA measurements. In HepG2HNF1Bkd cells LPA stimulation lead to downregulation of many pathways associated with cell cycle, lipid metabolism, and upregulation of steroid hormone metabolism and Wnt signaling. Also, increased intracellular protein level of autotaxin was detected in the cells. GSK-3alpha/beta protein level and its phosphorylated ratio were differentially affected by LPA stimulation in HNF1Bkd and control cells.CONCLUSIONS:
LPA is elevated in sera of patients with HNF1Bmut. LPA contributes to the pathogenesis of HNF1B-MODY by affecting Wnt/GSK-3 signaling.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Quinase 3 da Glicogênio Sintase
/
Doenças Renais Císticas
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Metabolomics
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Polônia